USC Researchers Identify Biomarker for Chemoimmunotherapy Treatment Response in NSCLC Patients
Researchers at the USC Norris Comprehensive Cancer Center have identified a biomarker called CX3CR1 that may be able to predict a patient’s response to chemotherapy and immunotherapy. Six to nine weeks after the patient begins therapy, a straightforward blood test can identify the biomarker, which is expressed on T-cells. After six and nine weeks of … Read more